Evidence map›Paper›PMID 32296841›Full record

ArticleNeuro-oncology2020

In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.

Alexandra K Bohm, Jessica DePetro, Carmen E Binding, Amanda Gerber, Nicholas Chahley, N Dan Berger, Mathaeus Ware, Kaitlin Thomas, U Senapathi, Shazreh Bukhari and 20 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 2 countries.

Alexandra K BohmThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Jessica DePetroThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Carmen E BindingThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Amanda GerberThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Nicholas ChahleyThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
N Dan BergerThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Mathaeus WareThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Kaitlin ThomasThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
U SenapathiThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Shazreh BukhariThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Cindy ChenThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Erin ChahleyThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Cameron GrisdaleHotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Sam LawnThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Yaping YuCharbonneau Cancer Institute, Calgary, Alberta, Canada.
Raymond Wongthe Hospital for Sick Children, Toronto, Ontario, Canada.
Yaoqing Shenthe Michael Smith Genome Sciences Centre and University of British Columbia, Vancouver, British Columbia, Canada.
Hiba OmairiThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Reza MirzaeiThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Nourah AlshattiThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Haley PedersenThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Wee YongThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Samuel WeissThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Jennifer ChanThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
P J Ciminothe Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington, USA.
John KellyThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Steve Jonesthe Michael Smith Genome Sciences Centre and University of British Columbia, Vancouver, British Columbia, Canada.
Eric Hollandthe Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington, USA.
Michael BloughThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
Gregory CairncrossThe Clark H Smith Brain Tumour Centre, Calgary, Alberta, Canada.
University of Calgary · CAUniversity of British Columbia · CAUniversity of Washington · USHospital for Sick Children · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImagining ways to prevent or treat glioblastoma (GBM) has been hindered by a lack of understanding of its pathogenesis. Although overexpression of platelet derived growth factor with two A-chains (PDGF-AA) may be an early event, critical details of the core biology of GBM are lacking. For example, existing PDGF-driven models replicate its microscopic appearance, but not its genomic architecture. Here we report a model that overcomes this barrier to authenticity.

methodsUsing a method developed to establish neural stem cell cultures, we investigated the effects of PDGF-AA on subventricular zone (SVZ) cells, one of the putative cells of origin of GBM. We microdissected SVZ tissue from p53-null and wild-type adult mice, cultured cells in media supplemented with PDGF-AA, and assessed cell viability, proliferation, genome stability, and tumorigenicity.

resultsCounterintuitive to its canonical role as a growth factor, we observed abrupt and massive cell death in PDGF-AA: wild-type cells did not survive, whereas a small fraction of null cells evaded apoptosis. Surviving null cells displayed attenuated proliferation accompanied by whole chromosome gains and losses. After approximately 100 days in PDGF-AA, cells suddenly proliferated rapidly, acquired growth factor independence, and became tumorigenic in immune-competent mice. Transformed cells had an oligodendrocyte precursor-like lineage marker profile, were resistant to platelet derived growth factor receptor alpha inhibition, and harbored highly abnormal karyotypes similar to human GBM.

conclusionThis model associates genome instability in neural progenitor cells with chronic exposure to PDGF-AA and is the first to approximate the genomic landscape of human GBM and the first in which the earliest phases of the disease can be studied directly.

Indexed as

Brain NeoplasmsGlioblastomaNeural Stem CellsPlatelet-Derived Growth FactorTumor Suppressor Protein p53AnimalsCells, CulturedLateral VentriclesMiceMice, Inbred C57BLPlatelet-Derived Growth Factorplatelet-derived growth factor ATrp53 protein, mouseTumor Suppressor Protein p53GBMgenome instabilityglioblastomamodelp53PDGF-AA

Identifiers

PMID32296841
PMCPMC7594559
OpenAlexW3016855810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.